Oxaliplatin
- Generic Name
- Oxaliplatin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C8H14N2O4Pt
- CAS Number
- 61825-94-3
- Unique Ingredient Identifier
- 04ZR38536J
- Background
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemic...
- Indication
Oxaliplatin, in combination with infusional fluorouracil and leucovorin, is indicated for the treatment of advanced colorectal cancer and adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.
- Associated Conditions
- Advanced Colorectal Cancer, Stage III Colon Cancer
- Associated Therapies
- -
HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-04-25
- Target Recruit Count
- 120
- Registration Number
- NCT06383078
Photoradiation with Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
- Conditions
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Endoscopic UltrasoundDrug: FluorouracilDrug: IrinotecanDrug: LeucovorinProcedure: Lymph Node BiopsyProcedure: Magnetic Resonance ImagingDrug: OxaliplatinBiological: PembrolizumabDrug: Photodynamic TherapyProcedure: Positron Emission TomographyOther: Questionnaire AdministrationDrug: Verteporfin
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 25
- Registration Number
- NCT06381154
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 56
- Registration Number
- NCT06368141
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM
- Conditions
- Interventions
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-04-02
- Target Recruit Count
- 40
- Registration Number
- NCT06341595
- Locations
- 🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China
A Phase II Multicenter Clinical Study of Improved Short-course Radiotherapy Combined With CAPOX and PD-1 Monoclonal Antibody for Locally Advanced Mid-low Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 31
- Registration Number
- NCT06333769
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
ELVN-002 with Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Enliven Therapeutics
- Target Recruit Count
- 275
- Registration Number
- NCT06328738
- Locations
- 🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇧🇪CHU de Liège, Liège, Belgium
🇧🇪GZA Ziekenhuizen - Campus Sint-Augustinus, Wilrijk, Belgium
Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-03-15
- Target Recruit Count
- 106
- Registration Number
- NCT06313801
- Locations
- 🇷🇺
Research Institute of Clinical Oncology "Nizhny Novgorod Regional Clinical Oncological Dispensary", Nizhny Novgorod, Russian Federation
Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial
- Conditions
- Interventions
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 30
- Registration Number
- NCT06310473
- Locations
- 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
- Conditions
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 156
- Registration Number
- NCT06280495
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-02-28
- Target Recruit Count
- 36
- Registration Number
- NCT06282445
- Locations
- 🇨🇳
The Fourth Affiliated Hospital Zhejiang University School of Medicine, Jinhua, Zhejiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.